Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression

被引：0
作者：
Weinstock, M. [1 ]
Luques, L.
Bejar, C.
Shoham, S.
机构：
[1] Hebrew Univ Jerusalem, Dept Pharmacol, Hadassah Med Sch, IL-91120 Jerusalem, Israel
[2] Herzog Hosp, Res Dept, Jerusalem, Israel
来源：
JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT | 2006年 / 70期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Ladostigil is a novel drug that inhibits acetyl and butyrylcholinesterase, and monoamine oxidase (MAO) A and B selectively in the brain. It reverses memory deficits induced by chronic inhibition of cortical cytochrome oxidase in rats and has anxiolytic and antidepressant-like activity in prenatally-stressed rats. Ladostigil also prevents oxidative-nitrative stress induced in astrocytes in the hippocampal CA1 region following icv injection of STZ in rats which also impairs their episodic memory. The unique combination of ChE and MAO enzyme inhibition combined with neuroprotection makes ladostigil a potentially useful drug for the treatment of dementia in subjects that also have extrapyramidal dysfunction and depression.
引用
收藏
页码：443 / 446
页数：4
相关论文
共 10 条
  • [1] Potential cognitive actions of (N-propargly-(3R)aminoindan-5-yl)-ethyl, methyl carbamate (TV3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task
    Buccafusco, JJ
    Terry, AV
    Goren, T
    Blaugrun, E
    [J]. NEUROSCIENCE, 2003, 119 (03) : 669 - 678
  • [2] Ellis JM, 2005, J AM OSTEOPATH ASSOC, V105, P145
  • [3] Mitochondrial abnormalities in Alzheimer's disease
    Hirai, K
    Aliev, G
    Nunomura, A
    Fujioka, H
    Russell, RL
    Atwood, CS
    Johnson, AB
    Kress, Y
    Vinters, HV
    Tabaton, M
    Shimohama, S
    Cash, AD
    Siedlak, SL
    Harris, PLR
    Jones, PK
    Petersen, RB
    Perry, G
    Smith, MA
    [J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (09) : 3017 - 3023
  • [4] Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease
    Kaasinen, V
    Någren, K
    Järvenpää, T
    Roivainen, A
    Yu, MX
    Oikonen, V
    Kurki, T
    Rinne, JO
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) : 615 - 620
  • [5] Immunohistochemical study of the expression of cytokines and nitric oxide synthases in brains of patients with dementia with Lewy bodies
    Katsuse, O
    Iseki, E
    Kosaka, K
    [J]. NEUROPATHOLOGY, 2003, 23 (01) : 9 - 15
  • [6] Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats
    Poltyrev, T
    Gorodetsky, E
    Bejar, C
    Schorer-Apelbaum, D
    Weinstock, M
    [J]. PSYCHOPHARMACOLOGY, 2005, 181 (01) : 118 - 125
  • [7] Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity
    Weinstock, M
    Shoham, S
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2004, 111 (03) : 347 - 366
  • [8] A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease
    Weinstock, M
    Gorodetsky, E
    Poltyrev, T
    Gross, A
    Sagi, Y
    Youdim, M
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (04) : 555 - 561
  • [9] Alterations induced by gestational stress in brain morphology and behaviour of the offspring
    Weinstock, M
    [J]. PROGRESS IN NEUROBIOLOGY, 2001, 65 (05) : 427 - 451
  • [10] Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-3R)aminoindan-5-YL)-ethyl methyl carbamate
    Youdim, MBH
    Weinstock, M
    [J]. CELLULAR AND MOLECULAR NEUROBIOLOGY, 2001, 21 (06) : 555 - 573
1